Patents by Inventor Paul Goldspink

Paul Goldspink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patient interface
    Patent number: 11931513
    Abstract: A patient interface for delivery of a supply of pressurised air or breathable gas to an entrance of a patient's airways comprising: a cushion member that includes a retaining structure and a seal-forming structure permanently connected to the retaining structure; a frame member attachable to the retaining structure; and a positioning and stabilising structure attachable to the frame member.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: March 19, 2024
    Assignee: ResMed Pty Ltd
    Inventors: Rupert Christian Scheiner, William Laurence Hitchcock, Anthony Paul Barbara, Adam Francis Barlow, Craig David Edwards, Lachlan Richard Goldspink, Kirrily Michele Haskard, Murray William Lee, Frederick Arlet May, Gerard Michael Rummery, Shiva Kumar Shanmuga Sundara, Chia Ik Tan, Stewart Joseph Wagner, Alicia Kristianne Wells, Martin Forrester, Ralph Jourdan
  • Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
    Publication number: 20180271942
    Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 27, 2018
    Inventors: Geoffrey Goldspink, Paul Goldspink
  • Use of the insulin-like-growth factor 1 splice variant MGF for the prevention of myocardial damage
    Patent number: 9919031
    Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: March 20, 2018
    Assignee: THE BOARD OF TRUSTEES OF UNIVERSITY OF ILLINOIS
    Inventors: Geoffrey Goldspink, Paul Goldspink
  • Temporal release of growth factors from 3D micro rod scaffolds for tissue regeneration
    Patent number: 8591933
    Abstract: The present invention relates to the use of three-dimensional microrod scaffolds for the temporal release of growth factors useful in tissue regeneration, engineering and treatment of disorders.
    Type: Grant
    Filed: January 19, 2010
    Date of Patent: November 26, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Brenda Russell, Tejal A. Desai, Paul Goldspink
  • Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage
    Publication number: 20130210723
    Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 15, 2013
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Geoffrey Goldspink, Paul Goldspink
  • TEMPORAL RELEASE OF GROWTH FACTORS FROM 3D MICRO ROD SCAFFOLDS FOR TISSUE REGENERATION
    Publication number: 20100158979
    Abstract: The present invention relates to the use of three-dimensional microrod scaffolds for the temporal release of growth factors useful in tissue regeneration, engineering and treatment of disorders.
    Type: Application
    Filed: January 19, 2010
    Publication date: June 24, 2010
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: BRENDA RUSSELL, Tejal A. Desai, Paul Goldspink
  • Use of the insulin-like-growth factor I splice variant MGF for the prevention of myocardial damage
    Publication number: 20080039390
    Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.
    Type: Application
    Filed: March 20, 2007
    Publication date: February 14, 2008
    Applicants: UNIVERSITY COLLEGE LONDON, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Geoffrey Goldspink, Paul Goldspink
  • Peptides
    Publication number: 20060211606
    Abstract: This invention relates to biologically active polypeptides derived from the E peptide that forms the C-terminus of the insulin-like growth factor I (IGF-I) splice variant known as mechano growth factor (MGF). These peptides are modified to improve their stability compared to the naturally occurring E peptide.
    Type: Application
    Filed: March 20, 2006
    Publication date: September 21, 2006
    Inventors: Geoffrey Goldspink, Shi Yang, Paul Goldspink
  • Use of the insulin-like-growth factor i splice variant mgf for the prevention of myocardial damage
    Publication number: 20050048028
    Abstract: The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium.
    Type: Application
    Filed: February 6, 2003
    Publication date: March 3, 2005
    Inventors: Geoffrey Goldspink, Paul Goldspink